CN1747729A - Janus酪氨酸激酶3(JAK3)的选择性抑制方法 - Google Patents

Janus酪氨酸激酶3(JAK3)的选择性抑制方法 Download PDF

Info

Publication number
CN1747729A
CN1747729A CNA2003801054687A CN200380105468A CN1747729A CN 1747729 A CN1747729 A CN 1747729A CN A2003801054687 A CNA2003801054687 A CN A2003801054687A CN 200380105468 A CN200380105468 A CN 200380105468A CN 1747729 A CN1747729 A CN 1747729A
Authority
CN
China
Prior art keywords
cell
jak3
chemical compound
inhibition
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2003801054687A
Other languages
English (en)
Chinese (zh)
Inventor
罗伯特·A·柯肯
巴里·D·卡汉
斯坦尼斯瓦夫·M·斯特普科夫斯基
沃尔德马·普里贝
伊莎贝拉·福克特
希蒙·科辛斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of CN1747729A publication Critical patent/CN1747729A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C07C225/12—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms being part of rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • G01N2333/91205—Phosphotransferases in general
    • G01N2333/9121—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases
    • G01N2333/91215—Phosphotransferases in general with an alcohol group as acceptor (2.7.1), e.g. general tyrosine, serine or threonine kinases with a definite EC number (2.7.1.-)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Surgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNA2003801054687A 2002-12-09 2003-12-09 Janus酪氨酸激酶3(JAK3)的选择性抑制方法 Pending CN1747729A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43185102P 2002-12-09 2002-12-09
US60/431,851 2002-12-09

Publications (1)

Publication Number Publication Date
CN1747729A true CN1747729A (zh) 2006-03-15

Family

ID=32507812

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2003801054687A Pending CN1747729A (zh) 2002-12-09 2003-12-09 Janus酪氨酸激酶3(JAK3)的选择性抑制方法

Country Status (17)

Country Link
US (2) US7365096B2 (https=)
EP (1) EP1578411A4 (https=)
JP (1) JP2006514021A (https=)
KR (1) KR20050084224A (https=)
CN (1) CN1747729A (https=)
AU (1) AU2003297740B2 (https=)
BR (1) BR0317099A (https=)
CA (1) CA2506432A1 (https=)
EC (1) ECSP055843A (https=)
HU (1) HUP0500844A2 (https=)
MX (1) MXPA05006133A (https=)
NO (1) NO20052497L (https=)
NZ (1) NZ540427A (https=)
PL (1) PL376844A1 (https=)
RU (1) RU2005121672A (https=)
WO (1) WO2004052359A1 (https=)
ZA (1) ZA200504163B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104090115A (zh) * 2014-07-10 2014-10-08 上海益诺思生物技术有限公司 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
JP4928937B2 (ja) 2003-03-28 2012-05-09 スローン−ケッタリング・インスティテュート・フォー・キャンサー・リサーチ ミグラスタチンアナログおよびその使用
BRPI0413018B8 (pt) 2003-07-30 2021-05-25 Rigel Pharmaceuticals Inc composto, e, uso de um composto
AU2005237254B2 (en) * 2004-05-03 2010-02-04 Novartis Ag Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor
WO2006001967A2 (en) 2004-05-25 2006-01-05 Sloan-Kettering Institute For Cancer Research Migrastatin analogs in the treatment of cancer
US8188141B2 (en) 2004-09-23 2012-05-29 Sloan-Kettering Institute For Cancer Research Isomigrastatin analogs in the treatment of cancer
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
EP1883302A4 (en) * 2005-05-03 2009-05-20 Rigel Pharmaceuticals Inc JAK KINASE HEMMER AND ITS USE
TR201802449T4 (tr) 2005-10-26 2018-03-21 Novartis Ag Ailesel akdeniz hummasının anti ıl-1beta antikorları ile tedavisi.
RU2487711C2 (ru) 2005-11-21 2013-07-20 Новартис Аг Лечение нейроэндокринных опухолей
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
EP2468301A1 (en) 2007-05-29 2012-06-27 Novartis AG New indications for anti-IL-1-beta therapy
WO2009060035A1 (en) 2007-11-08 2009-05-14 Novartis Ag Gene expression signatures for chronic/sclerosing allograft nephropathy
US8268834B2 (en) 2008-03-19 2012-09-18 Novartis Ag Pyrazine derivatives that inhibit phosphatidylinositol 3-kinase enzyme
CA2767616A1 (en) 2009-07-09 2011-01-13 The Scripps Research Institute Gene expression profiles associated with chronic allograft nephropathy
US8791100B2 (en) 2010-02-02 2014-07-29 Novartis Ag Aryl benzylamine compounds
UA112517C2 (uk) 2010-07-06 2016-09-26 Новартіс Аг Тетрагідропіридопіримідинові похідні
US9018006B2 (en) 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
JP2014518256A (ja) 2011-06-27 2014-07-28 ノバルティス アーゲー テトラヒドロ−ピリド−ピリミジン誘導体の固体形態および塩類
KR20140058543A (ko) 2011-07-08 2014-05-14 노파르티스 아게 신규 피롤로 피리미딘 유도체
WO2013057711A1 (en) 2011-10-21 2013-04-25 Novartis Ag Quinazoline derivatives as pi3k modulators
US20140348848A1 (en) 2011-12-02 2014-11-27 Dhananjay Kaul Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
DK2790705T3 (en) 2011-12-15 2018-03-12 Novartis Ag Use of inhibitors of the activity or function of PI3K
WO2013093850A1 (en) 2011-12-22 2013-06-27 Novartis Ag Quinoline derivatives
JP5903499B2 (ja) 2011-12-22 2016-04-13 ノバルティス アーゲー ジヒドロ−ベンゾ−オキサジンおよびジヒドロ−ピリド−オキサジン誘導体
US9371265B2 (en) * 2012-03-26 2016-06-21 Ep Pharma, Inc. Compositions and methods related to inhibitors of JAK kinase
TW201422625A (zh) 2012-11-26 2014-06-16 Novartis Ag 二氫－吡啶并－□衍生物之固體形式
WO2014128612A1 (en) 2013-02-20 2014-08-28 Novartis Ag Quinazolin-4-one derivatives
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
US9657007B2 (en) 2013-09-22 2017-05-23 Calitor Sciences, Llc Substituted aminopyrimidine compounds and methods of use
US9512084B2 (en) 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
KR20160141856A (ko) 2014-04-24 2016-12-09 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 피라진 유도체
KR20160145780A (ko) 2014-04-24 2016-12-20 노파르티스 아게 포스파티딜이노시톨 3-키나제 억제제로서의 아미노 피리딘 유도체
EP3134397A1 (en) 2014-04-24 2017-03-01 Novartis AG Amino pyrazine derivatives as phosphatidylinositol 3-kinase inhibitors
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
EP3146077A4 (en) 2014-05-22 2018-05-02 The Scripps Research Institute Tissue molecular signatures of kidney transplant rejections
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
AU2019209960B2 (en) 2018-01-20 2023-11-23 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
WO2020067887A1 (en) 2018-09-24 2020-04-02 Erasmus University Medical Center Rotterdam Specific inhibition of janus kinase 3 (jak3) for modulating anti-tumor immune responses
BR112021023054A2 (pt) 2019-05-23 2022-03-29 Novartis Ag Formas cristalinas de um inibidor de btk

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA712187A (en) * 1965-06-22 J. C. Buisson Paul 2-(2'-oxo-1'-cyclododecyl) acetic acid, the salts thereof, and process of preparing same
FR1466205A (fr) * 1960-04-01 1967-01-20 Chimie Atomistique Acide 1-cétocyclododécyl-2-acétique, ses sels et leur procédé de préparation
AU566673B2 (en) 1983-09-15 1987-10-29 F. Hoffmann-La Roche Ag Phenethylamine derivatives
US6136595A (en) * 1993-07-29 2000-10-24 St. Jude Children's Research Hospital Jak kinases and regulations of cytokine signal transduction
US6313129B1 (en) 1998-08-21 2001-11-06 Hughes Institute Therapeutic compounds
US6080747A (en) * 1999-03-05 2000-06-27 Hughes Institute JAK-3 inhibitors for treating allergic disorders
JP2003518023A (ja) * 1999-11-30 2003-06-03 パーカー ヒューズ インスティテュート トロンビン誘導血小板凝集の阻害剤
MY128450A (en) 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
CA2326952A1 (en) 2000-11-27 2002-05-27 The Hospital For Sick Children T cell protein tyrosine phosphatase

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104090115A (zh) * 2014-07-10 2014-10-08 上海益诺思生物技术有限公司 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法
CN104090115B (zh) * 2014-07-10 2016-01-13 上海益诺思生物技术有限公司 次级t细胞依赖抗体反应检测外源性化合物免疫抑制方法

Also Published As

Publication number Publication date
AU2003297740A1 (en) 2004-06-30
NO20052497L (no) 2005-09-02
ECSP055843A (es) 2005-11-22
US20050203177A1 (en) 2005-09-15
KR20050084224A (ko) 2005-08-26
US7365096B2 (en) 2008-04-29
MXPA05006133A (es) 2006-03-09
US20080167220A1 (en) 2008-07-10
EP1578411A4 (en) 2007-05-02
CA2506432A1 (en) 2004-06-24
RU2005121672A (ru) 2005-11-20
WO2004052359A1 (en) 2004-06-24
US7928062B2 (en) 2011-04-19
AU2003297740B2 (en) 2008-09-11
HUP0500844A2 (en) 2007-08-28
NO20052497D0 (no) 2005-05-24
ZA200504163B (en) 2007-03-28
JP2006514021A (ja) 2006-04-27
BR0317099A (pt) 2005-10-25
AU2003297740A2 (en) 2004-06-30
EP1578411A1 (en) 2005-09-28
NZ540427A (en) 2008-04-30
PL376844A1 (pl) 2006-01-09

Similar Documents

Publication Publication Date Title
CN1747729A (zh) Janus酪氨酸激酶3(JAK3)的选择性抑制方法
US10245262B2 (en) Immunological reagents and uses therefor
Betts et al. Targeting Aurora kinase A and JAK2 prevents GVHD while maintaining Treg and antitumor CTL function
US9301961B2 (en) Autoimmune and inflammatory disorder therapy
US20240350481A1 (en) Use of n-myristoyl transferase (nmt) inhibitors in the treatment of cancer, autoimmune disorders, and inflammatory disorders
US11312676B2 (en) Small molecule stimulators of steroid receptor coactivator proteins and their use in the treatment of cancer
US20210283091A1 (en) Decreasing immune activity through modulation of postcellular signaling factors
CN1094046A (zh) 取代的黄嘌呤衍生物
US12595227B2 (en) Compositions and methods for treatment of platinum-based chemotherapeutic resistant tumors
US20250122209A1 (en) Methods and compositions for drugs to treat ophthalmic diseases
Vafadari et al. Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway
US20080279866A1 (en) Induction of immunosuppression by inhibition of ATM
Jernberg‐Wiklund et al. Control of Apoptosis in Human Multiple Myeloma by Insulin‐like Growth Factor I (IGF‐I)
CN1658881A (zh) 抗炎组合物及其使用方法
US20160031957A1 (en) Inhibitors of the linear ubiquitin chain assembly complex (lubac) and related methods
US20260041653A1 (en) An hdac inhibitor for treating cancer with a modified stk11 activity or expression
AU2018299884A1 (en) Identification and use of cytotoxic T lymphocyte (CTL) antigen-specific target cell killing enhancer agents
CN1418111A (zh) 新型配体及其制备方法
Doelling et al. Carnosinylation of Cardiac Antigens Attenuates Immunogenic Responses and Improves Function in Failing Hearts
EASTEP HUNTER B DEAN, RORY A GREER, JESSICA A GREVEN, RYAN A TUCKEY, GUNNAR N EASTEP, DANIEL S ELSTON, THOMAS J BRETT, YUHUA SONG, ERIK D ROBERSON
EP1938838A1 (en) Histamine h3 agonist for use as therapeutic agent for lipid/glucose metabolic disorder
EP3797781A1 (en) Use of ec-7072 and synergic compositions thereof in treatment of chronic lymphocytic leukemia
Dong et al. α-Tocopheryl succinate induces apoptosis by targeting ubiquinone-binding
JPH03220124A (ja) グルタミン酸拮抗剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Open date: 20060315